Medical Patent News

RSS

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.

3 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

HemCon Medical Technologies to ask for reversal of jury verdict in chitosan patent case

HemCon Medical Technologies, Inc., announced today that it will ask a US District Court in New Hampshire to review and reverse a jury verdict based on a patent held by Marine Polymer Technologies, Inc. The jury awarded damages of $29.4 million against HemCon in the patent case. HemCon will ask the Court to review the validity of the patent and reverse the damage award.

30 Apr 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received a new patent in the United States.

30 Apr 2010

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

30 Apr 2010

Tomophase receives seventh U.S. Patent for OCTIS component

Tomophase Corporation, a leading developer of non-invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has received notification of the issuance of its seventh patent: Delivering Light via Optical Waveguide and Multi-view Optical Probe Head, U. S. Patent # 7,706,646.

29 Apr 2010

USPTO issues new patent to Applied Spine Technologies

Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".

29 Apr 2010

DFine granted US patent relating to StabiliT Vertebral Augmentation System

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that the United States Patent & Trademark Office has issued Patent 7,678,116 relating to the StabiliT® Vertebral Augmentation System. Two additional Notices of Allowance have also been issued with patents expected later this year.

29 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Complaint filed in Superior Court of the State of California, County of Santa Clara against TPL

Patriot Scientific Corporation today reported that on April 22, 2010 it filed an action in the Superior Court of the State of California, County of Santa Clara against Technology Properties Limited, LLC, the Company's joint venture partner in the management of the MMP portfolio of microprocessor patents, and Alliacense, LLC, the licensing division of TPL.

27 Apr 2010

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.

27 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Pro-Tect Pharmaceuticals, Inc. announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

26 Apr 2010

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Teva Pharmaceutical Industries Ltd. announced today that a jury returned a verdict in the U.S. District Court for the District of New Jersey finding that Nycomed's U.S. Patent No. 4,758,579 is not invalid. The Court has reserved decision on the issue of what, if any, effect to give to the jury's determinations in connection with the obviousness-type double patenting defenses, which Teva has argued is to be decided by the Court.

24 Apr 2010

European Patent Office intends to grant patent for Intezyne's IVECT Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne's breakthrough drug delivery technology, the IVECT Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues.

23 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan®, in 60 mg per 20 mL and 90 mg per 30 mL vials. IMS data indicate that the 2009 U.S. innovator market for these adenosine presentations approximated $124 million. The Company plans to launch the product upon expiry of applicable innovator patents.

23 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Medical Patent News

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

HemCon Medical Technologies to ask for reversal of jury verdict in chitosan patent case

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Tomophase receives seventh U.S. Patent for OCTIS component

USPTO issues new patent to Applied Spine Technologies

DFine granted US patent relating to StabiliT Vertebral Augmentation System

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Complaint filed in Superior Court of the State of California, County of Santa Clara against TPL

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

PRTT completes acquisition of multiple patents and patents-pending from Nectid

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

European Patent Office intends to grant patent for Intezyne's IVECT Method

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

FDA grants tentative approval for Sagent Pharmaceuticals' adenosine injection

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News